

May 03, 2024

Office of the Attorney General State of Vermont

via email to: AGO.highcostprescriptiondrugs@vermont.gov

Pursuant to 18 V.S.A.§4637, Biogen is hereby providing notice of the introduction of a new prescription drug in the commercial market, as detailed below:

NDC	Description	Date Commercially Available	Wholesale Acquisition Cost*
64406-0022-01	TOFIDENCE 200 mg/10 mL (20 mg/mL) in a single-dose vial	05/01/2024	\$1,110.00
64406-0023-01	TOFIDENCE 400 mg/20 mL (20 mg/mL) in a single-dose vial	05/01/2024	\$2,220.00
64406-0024-01	TOFIDENCE 80 mg/4 mL (20 mg/mL) in a single-dose vial	05/01/2024	\$444.00

^{*}Price to wholesalers, without regard to prompt pay or other discounts, rebates, chargebacks, or any fees paid to wholesalers for services performed. Does not represent prices charged to other customers or classes of trade.

Within 30 days, Biogen will provide further details as also required under this law. Please let me know if you need any additional information.

Best Regards,

Sooah Cheung

Associate Director, Contracts & Pricing Governance Biogen | 225 Binney Street | Cambridge, MA | 02142 Email: sooah.cheung@biogen.com | Direct: 781-464-1606